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Abstract
Previous studies of associations of forced expiratory lung volume in one second (FEV1) with
peak oxygen uptake (VO2peak) in chronic obstructive pulmonary disease (COPD) have not
taken sex, age and height related variance of dynamic lung volumes into account. Nor have
such demographic spread of spirometric measures been considered in studies comparing
VO2peak between COPD phenotypes characterized by degree of emphysema. We aimed to
assess the association of FEV1Z-score with VO2peak in COPD (n = 186) and investigate
whether this association differs between emphysema (E-COPD) and non-emphysema
(NE-COPD) phenotypes. Corresponding assessments using standardized percent predicted
FEV1 (ppFEV1) were performed for comparison. Additionally, phenotype related differences
in VO2peak were compared using FEV1Z-score and ppFEV1 as alternative expressions of
FEV1. E-COPD and NE-COPD were defined by transfer factor of the lung for carbon monox-
ide below and above lower limits of normal (LLN), respectively. The associations were
assessed in linear regression models. One unit reduction in FEV1Z-score was associated with
1.9 (95% CI 1.4, 2.5) ml/kg/min lower VO2peak. In stratified analyses, corresponding esti-
mates were 2.2 (95% CI 1.4, 2.9) and 1.2 (95% CI 0.2, 2.2) ml/kg/min lower VO2peak in
E-COPD and NE-COPD, respectively. The association did not differ statistically by COPD
phenotype (p-value for interaction = 0.153). Similar estimates were obtained in analyses
using standardized ppFEV1. Compared to NE-COPD, VO2peak was 2.2 (95% CI 0.8, 3.6) and
2.1 (95% CI 0.8, 3.5) ml/kg/min lower in E-COPD when adjusted for FEV1Z-score and ppFEV1,
respectively. In COPD, FEV1Z-score is positively associated with VO2peak. This association
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was stronger in E-COPD but did not differ statistically by phenotype. Both the association of
FEV1 with VO2peak and the difference in VO2peak comparing COPD phenotypes seems inde-
pendent of sex, age and height related variance in FEV1. Mechanisms leading to reduction in
FEV1 may contribute to lower VO2peak in E-COPD.
Introduction
In current strategic documents provided by the Global Initiative for Chronic Obstructive Lung
Disease (GOLD), the post-bronchodilator ratio of forced expiratory lung volume in one sec-
ond/forced vital capacity (FEV1/FVC) is the key diagnostic variable defining chronic obstruc-
tive pulmonary disease (COPD) [1]. Reduced FEV1 denotes the severity of airway obstruction
and may reflect the pathophysiological mechanism of expiratory flow limitation (EFL) at rest
or during exercise, characteristic of this disease [2].
Dynamic hyperinflation (DH), inflicting restrictive constraints on tidal volume expansion,
is a functional consequence of EFL [3] and associated with dyspnea and exercise limitation in
COPD [4]. Exercise intolerance from dyspnea on exertion is a major manifestation of COPD
leading to physical inactivity, deconditioning and reduced exercise capacity [5]. Assessed by
cardiopulmonary exercise testing (CPET), peak oxygen uptake (VO2peak) is a direct measure of
exercise capacity and reduced values are associated with increased mortality in COPD [6].
Although integrated in the concept of ventilatory limitation to exercise, variables of airway
obstruction and exercise capacity are not strongly associated in COPD [7–9]. However, previ-
ous studies have not adequately taken sex, age and height related variance of dynamic lung vol-
umes into account when reporting associations of FEV1 with VO2peak among those with
COPD. Furthermore, the specificity of the diagnostic criterion of airway obstruction, when
defined by the fixed ratio of post-bronchodilator FEV1/FVC less than 0.70, is age dependent
and may lead to over-diagnosis of COPD in an older population [10–12]. In contrast to per-
cent predicted FEV1 (ppFEV1), and the fixed ratio of FEV1/FVC, Z-scores of these measures
provide spirometric expressions that are comparable independent of sex, age and height. Ref-
erence equations for the calculation of Z-scores of dynamic lung volumes are readily available
[13], and both the American Thoracic Society (ATS) and the European Respiratory Society
(ERS) have endorsed defining the lower limit of normal (LLN) of lung function measures by
the fifth percentile (z-score = -1.645) [14].
COPD is recognized as a heterogeneous disease and different phenotypes have been pro-
posed [15]. In patients with predominantly emphysema (E-COPD), destruction of the pulmo-
nary parenchyma leads to increased compliance from loss of elastic recoil pressure
predisposing dynamic compression of the airways. The non-emphysema (NE-COPD) pheno-
type is characterized by airway inflammation with intrinsic caliber reduction and increased
airflow resistance. These two phenotypes represent pathophysiological diversity in COPD
highlighting mechanisms contributing to reduced FEV1 and expiratory flow limitation.
The transfer factor of the lung for carbon monoxide (TLCO) has been used to differentiate
E-COPD from NE-COPD [14]. Patients with reduced TLCO have been shown to have lower
VO2peak than patients with more preserved TLCO when compared at similar ppFEV1 [4]. It is
unknown whether this difference in VO2peak is related to normalization of FEV1 by ppFEV1,
and/or whether the association of FEV1 with VO2peak is stronger in E-COPD than in
NE-COPD. Alternatively, mechanisms unrelated to FEV1 may explain the difference in exer-
cise capacity comparing these COPD phenotypes.
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Classification of patients by COPD phenotypes should be related to differences in clinically
important outcomes [16]. New knowledge on associations between major diagnostic and
prognostic measures in readily identifiable phenotypes of this multifaceted disease is likely to
be of scientific and clinical value. We aimed to assess the association of FEV1Z-score with
VO2peak in COPD and investigate whether this association differs comparing phenotypes with
and without emphysema. Additionally, we explored the potential influence of sex, age and
height related variance in FEV1 on both the association of FEV1 with VO2peak and on the dif-
ference in VO2peak between E-COPD and NE-COPD.
Materials and methods
Study population
We assessed patients referred for evaluation with pulmonary function tests (PFT) and CPET
due to exercise intolerance at a private specialist clinic in Norway (Telemark Heart Lung and
Blood Institute) between May 1999 and November 2014. The clinical database was accessed in
the time period between the fifteenth of July and the thirtieth of August 2015. Patients with
COPD (n = 301) were included.
In this study, the diagnostic criterion of airway obstruction in COPD was defined by the
post-bronchodilator FEV1/FVC less than LLN. E-COPD and NE-COPD phenotypes were defined
by TLCO below and above LLN, respectively [14]. LLN was defined as the fifth percentile (z-score
= -1.645). Predicted values and Z-scores of dynamic lung volumes and lung diffusing capacity
measures were calculated using the Global Lung Function Initiative (GLI) software [17, 18].
Patients > 80 years of age (n = 6) were excluded due to having an age above the valid range
of the GLI 2017 reference values for TLCO. Patients� 45 years of age (n = 28) were excluded
due to low prevalence of COPD in this age group. We excluded 33 patients with a clinical diag-
nosis of asthma. In order to ensure uniform modality of exercise testing, 13 patients were
excluded due to having performed the CPET on a treadmill. Furthermore, 19 patients were
excluded because of termination of CPET due to chest pain and electrocardiogram (ECG)
changes suggestive of myocardial ischemia (n = 2), arrhythmia or high blood pressure (n = 9),
leg/knee or hip-pain (n = 4), caution due to known aortic valve disease or aortic aneurysm
(n = 2), inadequate cycling technique (n = 1) or lack of motivation (n = 1). We also excluded
11 patients who performed PFT and CPET more than 3 months apart.
Three patients were excluded due to missing values on TLCO and two patients due to miss-
ing values on smoking status. After exclusions, 186 patients remained in the statistical analyses.
Pulmonary function tests
Spirometry and lung diffusing capacity (Vmax Legacy/Spectra 229; SensorMedics) were tested
on separate visits, but no more than 3 months prior to CPET (exclusion criterion). The proce-
dures adhered to recommendations provided by the American Thoracic Society/European
Respiratory Society guidelines [19, 20].
Cardiopulmonary exercise test
An incremental exercise test was performed on a cycle ergometer (ER900; Ergoline). The work
rate was increased by 5–25 W/minute on an individualized basis aiming for test termination
after 8–12 minutes. The patients reported the dominating symptom limiting further exercise
as dyspnea, leg discomfort/fatigue or other. The reasons for test termination in the latter cate-
gory included pain in lower extremities (n = 9), vertigo (n = 4) and attainment of estimated
maximal heart rate (n = 1).
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Breath by breath measurements (Vmax Legacy/Spectra 229; SensorMedics) of oxygen
uptake (VO2) and carbon dioxide output (VCO2) were averaged over 20 seconds. The highest
value of VO2 was normalized by bodyweight and termed VO2peak.
Pulse oximetry (SpO2) was measured continuously from rest to test termination using a fin-
ger probe (Model 340; Palco Labs/8600; Nonin). The minimum value was termed SpO2min.
Maximal voluntary ventilation (MVV) was estimated by FEV1 x 40 [21]. Ventilatory reserve
(VR) was calculated as VR = 1 –Minute ventilation at peak exercise (VEpeak)/MVV [22]. Maxi-
mal heart rate (HRmax) was estimated by 220 –age. Heart rate reserve (HRR) was calculated as
HRR = 1 –Heart rate at peak exercise (HRpeak)/HRmax [22].
Statistical analyses
Descriptive statistics, calculated as mean and standard deviation (SD) or number of observa-
tions and percentages, are reported for both the total sample and the sample stratified by
COPD phenotype. Lung function and exercise variables were compared between patients with
E-COPD and NE-COPD using independent samples t-tests.
The association of FEV1Z-score with VO2peak was investigated in linear regression models. In
a total sample model, VO2peak was regressed on FEV1Z-score and COPD phenotype. Body mass
index (BMI), smoking status (former or current), beta-blocker and bronchodilator treatment
(both dichotomous), were considered potential confounders. In separate models adjustments
were also made for sex and age due to known strong associations with VO2peak. An interaction
term (FEV1Z-score x COPD phenotype) was included in a separate analysis to investigate effect
modification of COPD phenotype on the association of FEV1Z-score with VO2peak. Due to
potential lack of power in the interaction analysis, the associations of FEV1Z-score with VO2peak
were also estimated in analyses stratified by COPD phenotype. Corresponding analyses with
standardized ppFEV1, calculated as (observed value–sample mean)/SD, were performed for
comparison. Regression coefficients (β) with 95% confidence intervals (CI) are reported.
Linear regression models were also used to investigate whether the difference in VO2peak
between E-COPD and NE-COPD is influenced by sex, age and height related variance in
FEV1. VO2peak was regressed on COPD phenotype, FEV1Z-score and ppFEV1 in separate models
adjusted for sex, age, BMI, smoking status, beta-blocker and bronchodilator treatment.
The potential influence of effort dependent underestimation of maximal exercise capacity
from VO2peak was evaluated in a sensitivity analysis including only those with reduced VR
and/or HRR. VO2peak was regressed on FEV1Z-score and COPD phenotype with adjustment for
age, sex, BMI, smoking status, beta-blocker and bronchodilator treatment.
Residual plots were inspected in all models, and no violations of the assumptions of linear
regression were uncovered. Statistical analyses were performed with IBM SPSS Statistics Ver-
sion 25 (IBM Corp., Armonk, NY, USA).
Ethics approval
The Regional Committee for Medical and Health Research Ethics approved this retrospective
study and the use of anonymous data without informed consent (REC-Central 2012/673).
Results
Clinical characteristics and PFT measures
The majority of patients were men, in both the total cohort (65%) and in subgroups stratified
by COPD phenotype (63% vs. 67% in E-COPD and NE-COPD, respectively). Mean values of
age, BMI and SpO2 at rest were similar in both phenotypes (63.9 vs. 60.4 years, 25.6 vs. 26.7
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kg/m2 and 95.1 vs. 96.0% in E-COPD and NE-COPD, respectively). All patients were former
or current smokers with similar proportions in both phenotypes (current smokers; 51% vs.
49% in E-COPD and NE-COPD, respectively). The majority of patients did not receive any
beta-blocker (67% vs. 76% in E-COPD and NE-COPD, respectively), but had ongoing bron-
chodilator treatment (73% vs. 53% in E-COPD and NE-COPD, respectively) (Table 1).
Compared to patients with NE-COPD, patients with E-COPD had lower FEV1Z-score (dif-
ference 0.69, 95% CI 0.36, 1.02, p< 0.001), lower FVCZ-score (difference 0.42, 95% CI 0.05,
0.79, p = 0.028), lower (FEV1/FVC)Z-score (difference 0.62, 95% CI 0.38, 0.86, p< 0.001), lower
KCOZ-score (difference 1.74, 95% CI 1.40, 2.07, p< 0.001), lower VAZ-score (difference 0.91,
95% CI 0.56, 1.27, p< 0.001) and, by definition, lower TLCOZ-score (difference 2.41, 95% CI
2.14, 2.68, p< 0.001) (Table 1).
CPET measures
The majority of patients reported test termination due to dyspnea in both phenotypes, but the
proportion was higher in E-COPD than in NE-COPD (67 vs. 52%). The proportion reporting
test termination due to leg fatigue was lower in E-COPD than in NE-COPD (26 vs. 40%)
(Table 2).
Table 1. Clinical characteristics and pulmonary function test measures in total cohort and stratified by emphysema (E) and non-emphysema (NE) COPD
phenotypes.
Total E-COPD NE-COPD p-value
(n = 186) (n = 101) (n = 85)
Men/women 121 (65)/65 (35) 64 (63)/37 (37) 57 (67)/28 (33)
Age (years) 62.3 ± 8.9 63.9 ± 9.3 60.4 ± 8.0
BMI (kg/m2) 26.1 ± 3.6 25.6 ± 3.7 26.7 ± 3.4
SpO2 (%)
a 95.5 ± 2.0 95.1 ± 2.2 96.0 ± 1.6
Former/current smokers 92 (49)/94 (51) 49 (49)/52 (51) 43 (51)/42 (49)
Beta-blocker 53 (28) 33 (33) 20 (24)
Bronchodilator 119 (64) 74 (73) 45 (53)
FEV1 (L) 2.06 ± 0.77 1.82 ± 0.73 2.33 ± 0.73
FEV1Z-score -2.16 ± 1.21 -2.48 ± 1.24 -1.78 ± 1.06 < 0.001
ppFEV1 (%) 65.8 ± 19.8 59.8 ± 20.7 72.8 ± 16.2
FVC (L) 3.77 ± 1.10 3.58 ± 1.02 4.00 ± 1.15
ppFVC (%) 93.4 ± 19.4 90.5 ± 20.2 96.8 ± 17.8
FVCZ-score -0.45 ± 1.29 -0.65 ± 1.33 -0.23 ± 1.21 0.028
FEV1/FVC 0.54 ± 0.10 0.50 ± 0.11 0.58 ± 0.07
(FEV1/FVC)Z-score -2.84 ± 0.92 -3.12 ± 1.02 -2.50 ± 0.63 < 0.001
KCO (mmol/min/kPa/L) 6.07 ± 2.05 4.80 ± 1.20 7.57 ± 1.82
KCOZ-score -1.98 ± 1.54 -3.08 ± 1.10 -0.67 ± 0.77 < 0.001
VA (L) 5.44 ± 1.33 5.13 ± 1.22 5.82 ± 1.38
VAZ-score -0.70 ± 1.30 -1.12 ± 1.29 -0.21 ± 1.14 < 0.001
TLCO (mmol/min/kPa) 1.13 ± 0.29 0.96 ± 0.23 1.32 ± 0.23
TLCOZ-score -1.47 ± 1.43 -2.27 ± 1.22 -0.53 ± 1.05 < 0.001
Values are mean ± standard deviation or number of observations (percentages). COPD–chronic obstructive pulmonary disease, BMI–body mass index, SpO2 –pulse
oximetry, FEV1 –forced expiratory lung volume in one second, pp–percent predicted, FVC–forced vital capacity, KCO–diffusion constant for carbon monoxide, VA–
alveolar volume, TLCO–transfer factor of the lung for carbon monoxide.
an = 181: Emphysema/non-emphysema = 98/83.
https://doi.org/10.1371/journal.pone.0252386.t001
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Compared to patients with NE-COPD, patients with E-COPD had lower VO2peak (differ-
ence 4.8 ml/kg/min, 95% CI 3.0, 6.5, p< 0.001), lower RERpeak (difference 0.04 95% CI 0.004,
0.08, p = 0.031), higher HRR (difference 6.1%, 95% CI 2.5, 9.6, p = 0.001), lower VEpeak (differ-
ence 14.8 l/min, 95% CI 7.8, 21.9, p< 0.001), lower VR (difference 5.5%, 95% CI -0.5, 11.5,
p = 0.073) and lower SpO2min (difference 1.7%, 95% CI 0.9, 2.6, p < 0.001) (Table 2).
Associations of FEV1Z-score with VO2peak and effect modification by COPD
phenotype
Adjusted for COPD phenotype, sex, age, BMI, smoking status, beta-blocker and bronchodila-
tor treatment, one unit reduction in FEV1Z-score (i.e. one SD reduction in FEV1) was, on aver-
age, associated with 1.9 (95% CI 1.4, 2.5) ml/kg/min lower VO2peak (Table 3).
Table 2. Cardiopulmonary exercise test measures in total cohort and stratified by emphysema (E) and non-emphysema (NE) COPD phenotypes.
Total E-COPD NE-COPD p-value
(n = 186) (n = 101) (n = 85)
Test termination
Dyspnea 112 (60) 68 (67) 44 (52)
Leg fatigue 60 (32) 26 (26) 34 (40)
Othera 14 (8) 7 (7) 7 (8)
VO2peak (ml/kg/min) 20.9 ± 6.5 18.7 ± 5.5 23.5 ± 6.6 < 0.001
RERpeak 1.11 ± 0.13 1.09 ± 0.14 1.13 ± 0.13 0.031
HRR (%)b 9.9 ± 12.7 12.7 ± 12.9 6.6 ± 11.6 0.001
VEpeak (L/min) 67.9 ± 25.2 61.1 ± 22.6 76.0 ± 25.9 < 0.001
MVV (L/min) 82.2 ± 30.8 72.9 ± 29.1 93.3 ± 29.2
VR (%) 14.5 ± 20.9 11.9 ± 23.0 17.5 ± 17.7 0.073
SpO2min (%)
c 94.3 ± 3.2 93.5 ± 3.6 95.3 ± 2.2 < 0.001
Values are mean ± standard deviation or number of observations (percentages). COPD–chronic obstructive pulmonary disease, VO2peak−oxygen uptake at peak
exercise, RERpeak−respiratory exchange ratio at peak exercise, HRR–heart rate reserve, VEpeak−minute ventilation at peak exercise, MVV–maximal voluntary
ventilation, VR–ventilatory reserve, SpO2min−minimum value pulse oximetry.
aPain in lower extremities (n = 9). Vertigo (n = 4). Attainment of estimated maximal heart rate (n = 1).
bn = 185: Emphysema/non-emphysema = 100/85.
cn = 185: Emphysema/non-emphysema = 101/84.
https://doi.org/10.1371/journal.pone.0252386.t002
Table 3. Associations of FEV1Z-score with VO2peak (ml/kg/min) in total cohort and stratified by emphysema (E) and non-emphysema (NE) COPD phenotypes.
Model 1a Model 2b Model 3c Model 4d
n β 95% CI β 95% CI β 95% CI β 95% CI
Totale 186 1.6 0.9, 2.3 2.0 1.4, 2.6 2.1 1.5, 2.6 1.9 1.4, 2.5
E-COPD 101 1.6 0.7, 2.4 2.0 1.3, 2.7 2.2 1.5, 2.9 2.2 1.4, 2.9
NE-COPD 85 1.6 0.3, 2.9 2.0 0.9, 3.1 1.6 0.6, 2.6 1.2 0.2, 2.2
FEV1Z-score−forced expiratory lung volum in one second Z-score, VO2peak−peak oxygen uptake, COPD–chronic obstructive pulmonary disease, β–regression coefficient,
CI–confidence interval.
aCrude association.
bAdjusted for sex and age (years).
cAdjusted for sex, age, body mass index (BMI) and smoking status (former, current).
dAdjusted for sex, age, BMI, smoking status, systemic beta-blocker (yes, no) and inhaled bronchodilator (yes, no).
eAdjusted for COPD phenotype in all total sample models.
https://doi.org/10.1371/journal.pone.0252386.t003
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Stratified by COPD phenotype, one unit reduction in FEV1Z-score was, on average, associ-
ated with 2.2 (95% CI 1.4, 2.9) and 1.2 (95% CI 0.2, 2.2) ml/kg/min lower VO2peak in E-COPD
and NE-COPD, respectively after adjustment for sex, age, BMI, smoking status, beta-blocker
and bronchodilator treatment (Table 3). The association of FEV1Z-score with VO2peak did not
differ statistically by phenotype (p-value for interaction = 0.153).
Associations of standardized ppFEV1 with VO2peak and effect modification
by COPD phenotype
Adjusted for COPD phenotype, sex, age, BMI, smoking status, beta-blocker and bronchodila-
tor treatment, one unit reduction in standardized ppFEV1 (i.e. one SD reduction in ppFEV1)
was, on average, associated with 2.5 (95% CI 1.8, 3.2) ml/kg/min lower VO2peak (Table 4).
Stratified by COPD phenotype, one unit reduction in standardized ppFEV1 was, on aver-
age, associated with 2.7 (95% CI 1.8, 3.6) and 1.6 (95% CI 0.3, 2.9) ml/kg/min lower VO2peak in
E-COPD and NE-COPD, respectively after adjustment for sex, age, BMI, smoking status, beta-
blocker and bronchodilator treatment (Table 4). The association of standardized ppFEV1 with
VO2peak did not differ statistically by phenotype (p-value for interaction = 0.220).
Phenotype related differences in VO2peak between FEV1Z-score and ppFEV1
Adjusted for sex, age, BMI, smoking status, beta-blocker and bronchodilator treatment,
VO2peak was, on average, 2.2 (95% CI 0.8, 3.6) and 2.1 (95% CI 0.8, 3.5) ml/kg/min lower in
E-COPD than in NE-COPD, when comparisons were made at similar FEV1Z-score
and ppFEV1, respectively.
Sensitivity analyses
In the sensitivity analyses including only those with reduced VR and/or HRR, one unit reduc-
tion in FEV1Z-score was, on average, associated with 2.2 (95% CI 1.5, 2.8) ml/kg/min lower
VO2peak after adjustment for COPD phenotype, sex, age, BMI, smoking status, beta-blocker
and bronchodilator treatment.
Stratified by COPD phenotype, one unit reduction in FEV1Z-score was, on average, associ-
ated with 2.5 (95% CI 1.6, 3.4) and 1.3 (95% CI 0.3, 2.3) ml/kg/min lower VO2peak in E-COPD
(n = 68) and NE-COPD (n = 66), respectively after adjustment for sex, age, BMI, smoking
Table 4. Associations of standardized ppFEV1 with VO2peak (ml/kg/min) in total cohort and stratified by emphysema (E) and non-emphysema (NE) COPD
phenotypes.
Model 1a Model 2b Model 3c Model 4d
n β 95% CI β 95% CI β 95% CI β 95% CI
Totale 186 2.5 1.6, 3.3 2.6 1.8, 3.3 2.7 2.0, 3.3 2.5 1.8, 3.2
E-COPD 101 2.4 1.4, 3.3 2.5 1.7, 3.3 2.7 1.9, 3.5 2.7 1.8, 3.6
NE-COPD 85 2.6 0.9, 4.3 2.6 1.2, 4.0 2.0 0.7, 3.3 1.6 0.3, 2.9
ppFEV1 –percent predicted forced expiratory lung volum in one second, VO2peak−peak oxygen uptake, COPD–chronic obstructive pulmonary disease, β–regression
coefficient, CI–confidence interval.
aCrude association.
bAdjusted for sex and age (years).
cAdjusted for sex, age, body mass index (BMI) and smoking status (former, current).
dAdjusted for sex, age, BMI, smoking status, systemic beta-blocker (yes, no) and inhaled bronchodilator (yes, no).
eAdjusted for COPD phenotype in all total sample models.
https://doi.org/10.1371/journal.pone.0252386.t004
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status, beta-blocker and bronchodilator treatment. The association of FEV1Z-score with VO2peak
did not differ statistically by phenotype (p-value for interaction = 0.051).
Adjusted for sex, age, BMI, smoking status, beta-blocker and bronchodilator treatment,
VO2peak was, on average, 2.0 (95% CI 0.3, 3.6) ml/kg/min lower in E-COPD than in
NE-COPD, when comparisons were made at similar FEV1Z-score.
Discussion
In this study we found FEV1Z-score to be positively associated with VO2peak. This association
was stronger in E-COPD than in NE-COPD but did not differ statistically by phenotype. In
corresponding analyses with standardized ppFEV1, similar estimates were observed. Exercise
capacity was lower in E-COPD than in NE-COPD, but the phenotype related differences in
VO2peak were similar when comparisons were made using FEV1Z-score and ppFEV1.
Previous studies have reported weak positive associations between measures of dynamic
lung volumes and exercise capacity in patients with COPD [8, 9]. Weak positive correlations
between FEV1 and VO2peak may be expected in a heterogeneous disease where multiple organ
systems and pathophysiological mechanisms interact and contribute in a highly variable man-
ner to exercise limitation in individual patients [23]. However, normalization of FEV1 by
using percent predicted may also weaken the association with VO2peak, especially in diverse
study populations with regards to sex, age and height. The present study is the first to report
the association of FEV1 with VO2peak in COPD using Z-scores of FEV1/FVC and FEV1 to
define both the presence of as well as the degree of airway obstruction, respectively. Although,
we support the use of Z-scores of dynamic lung volumes in the diagnostic process in COPD,
the associations of FEV1 with VO2peak were similar using FEV1Z-score and standardized
ppFEV1. Thus we have no reason to state that Z-scores are preferable over percent predicted
regarding the association of FEV1 with VO2peak in COPD. On average, one unit reduction in
FEV1Z-score was associated with 1.9 ml/min/kg (95% CI 1.4, 2.5) lower VO2peak. The minimal
clinically important difference in VO2peak has not been established in COPD, but we consider
this magnitude, representing 9% of the mean VO2peak (20.9 ml/kg/min) in this sample, likely
to represent variability in functional impairment.
Several studies have reported differences in exercise capacity for any given reduction in
ventilatory capacity when comparing patients with COPD phenotypically stratified by degree
of emphysema. O‘Donnell et al. [4] reported lower VO2peak in patients with COPD and
reduced TLCO (38 ± 8% predicted) compared to patients with similar ppFEV1 but more pre-
served TLCO (73 ± 4% predicted). Farkhooy et al. [24] found TLCO to be an independent pre-
dictor of exercise capacity, assessed by peak workload, in patients with varying severity of
COPD. Consistent with the results of these studies, we found lower VO2peak in patients with
E-COPD defined by TLCO below LLN. The estimated difference in VO2peak comparing
E-COPD and NE-COPD was 2.2 (95% CI 0.8, 3.6) and 2.1 (95% CI 0.8, 3.5) ml/kg/min when
patients were compared at similar FEV1Z-score and ppFEV1, respectively. Thus, the difference
in exercise capacity comparing these two COPD phenotypes seems independent of sex, age
and height related variance in FEV1. In fact, lower exercise capacity in E-COPD seems to be
conditional on pathophysiological mechanisms unrelated to reduction in ventilatory capacity
as estimated from FEV1.
In a small study of patients with COPD and moderate to severe emphysema (n = 16), Pao-
letti et al. [25] compared the ventilatory response to maximal incremental exercise between
patients with degree of emphysema above and below 50% as measured by high resolution com-
puted tomography. In the group with over 50% emphysema, there was evidence of more
dynamic hyperinflation, higher tidal volume to inspiratory capacity ratio (VT/IC), higher end-
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tidal partial pressure of CO2 (PETCO2) as well as increasing arterial partial pressure of CO2
(PaCO2) at peak exercise, suggesting greater mechanical constraints and relative hypoventila-
tion in this group. O‘Donnell et al. [4] also found more dynamic hyperinflation at lower exer-
cise levels, more rapid attainment of volume constraints and higher degree of exercise induced
dyspnea in patients with COPD and lower compared to higher TLCO. We found both lower
VR, suggesting higher ventilatory demand at peak exercise relative to estimated maximal venti-
latory capacity, and a higher proportion reporting test termination due to dyspnea in E-COPD
compared to NE-COPD. Mechanical ventilatory limitation may therefore be a principal patho-
physiological mechanism explaining the difference in exercise capacity between patients with
E-COPD and NE-COPD found in our study.
Since lower aerobic capacity in E-COPD seems to be unrelated to ventilatory capacity, we
may also hypothesize that greater inclination to mechanical ventilatory limitation is caused by
increased ventilatory demand due to more pronounced gas exchange abnormalities and venti-
latory inefficiency in E-COPD. Unfortunately, due to technical problems in the initial data
extracting process, only peak exercise data were available and measures of ventilatory effi-
ciency were therefore not included in this study. However, Rinaldo et al. [26] recently reported
differences in ventilatory efficiency when comparing noninvasive measures between patients
with emphysema and non-emphysema COPD phenotypes. The ventilatory equivalents for
CO2 (VE/VCO2), both nadir and slope below ventilatory compensation point, were higher in
emphysema indicating more pronounced ventilatory inefficiency in this phenotype.
Although we did not find strong evidence to support an effect modification of COPD phe-
notype on the association between FEV1Z-score and VO2peak (p-value for interaction 0.153), the
estimated association was stronger in E-COPD (2.2 ml/kg/min, 95% CI 1.4, 2.9) than in
NE-COPD (1.2 ml/kg/min, 95% CI 0.2, 2.2). Therefore, we cannot exclude the possibility that,
additionally to being a marker of ventilatory capacity, any reduction in FEV1 may either
impact or reflect gas exchange, ventilation/perfusion (V/Q) heterogeneity and ventilatory effi-
ciency differently depending on COPD phenotype. Interestingly, although not confirmative of
such speculation, we did find lower SpO2min in E-COPD compared to NE-COPD. Future stud-
ies are warranted and should aim to address underlying pathophysiological mechanisms
explaining differences in exercise capacity comparing E-COPD and NE-COPD. In this regard,
we believe invasive measures of gas exchange and calculations of dead space ventilation from
arterial blood gasses would be beneficial.
Boutou et al. [27] found percent predicted TLCO (ppTLCO) to be an independent predictor
of survival in patients with COPD, and the impact of VO2peak on mortality is well known in
this disease [6]. By confirming a positive association between phenotype assessment by
TLCOZ-score and VO2peak, the present study provides additional evidence linking two prognos-
tic measures in COPD. In agreement with previous studies [24–27], we advocate that assess-
ment of TLCO should be considered in the evaluation of patients with COPD to add clinical
information not inferable from simple spirometric measurements alone. Furthermore, the
finding of both lower FEV1Z-score and VO2peak in patients with E-COPD, coincide with COPD
phenotype being a positive modifier of the association between these key variables. We suggest
that differentiation between TLCO below and above LLN should complement measures of
dynamic lung volumes in future studies of exercise capacity in COPD.
A strength of the current study is that we used Z-scores of lung function measures when
reporting the association of FEV1 with VO2peak. This approach is novel and E-COPD and
NE-COPD may be more correctly differentiated by TLCOZ-score, taking sex, age and height
related variance into account, than by ppTLCO. Furthermore, confounding effects of sex and
age on the association of FEV1z-score with VO2peak are likely to reflect sampling variation,
which was explored in a separate model. Additionally, the patients assessed in this study were
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referred for evaluation from primary care and may represent patients typically encountered in
a specialist clinic for diagnostic or prognostic evaluation of COPD.
This study has limitations. COPD phenotypes were dichotomized into E-COPD and
NE-COPD based on TLCO below and above LLN, respectively. Although the pre-test probabil-
ity for emphysema is assumed high in this study population consisting of patients with COPD,
radiological qualitative and quantitative confirmation by thoracic computed tomography was
not available. On the other hand, this is a real life study and assessment of emphysematous
component by TLCO in obstructive lung disease is recommended in clinical practice [14].
The gold standard to assess exercise capacity is direct measurement of VO2 at maximal
exercise (VO2max). VO2peak, used in this study, is susceptible to patient effort and may underes-
timate true VO2max [28]. Provided that any underestimation of VO2max from VO2peak is unre-
lated to FEV1Z-score, only the precision of the estimates should potentially be influenced. In
contrast, associations between underestimation of VO2max from VO2peak and FEV1Z-score could
introduce systematic error and bias the results. We identified 52 patients (E-COPD; n = 33)
with both VR above 15% and HRR above 10%, potentially indicative of submaximal effort, i.e.
both preserved residual capacity of the ventilatory and cardiac system, respectively [22].
Excluding these patients in the sensitivity analyses did not appreciably influence the estimates.
In this cross sectional study we can only test for associations. The nature of the data does
not permit causal inference or definite conclusions on involved pathophysiological mecha-
nisms behind observed results. Therefore, the clinical value of differentiation on COPD phe-
notype, supported by this study, cannot be extended to suggest specific treatment
recommendations in individual patients.
Conclusions
In COPD, FEV1Z-score is positively associated with VO2peak. This association was stronger in
E-COPD than in NE-COPD but did not differ statistically by phenotype. Both the association
of FEV1 with VO2peak and the difference in VO2peak comparing COPD phenotypes seems inde-
pendent of sex, age and height related variance in FEV1. Mechanisms leading to reduction in
FEV1 may contribute to lower VO2peak in E-COPD. Future studies aiming to address underly-
ing pathophysiological mechanisms of these findings are warranted.
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